News
-
-
PRESS RELEASE
EQS-Adhoc: M1 Kliniken AG: Supervisory Board approves 2023 annual financial statements. Dividend proposal of EUR 0.50 per share
M1 Kliniken AG's Supervisory Board approves 2023 financial statements with EUR 0.50 per share dividend proposal. Anticipates sales and earnings growth in 2024 -
-
PRESS RELEASE
Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH): Kaufen
First Berlin Equity Research GmbH releases a research update on M1 Kliniken AG, reiterating a BUY rating and EUR 18.00 price target, based on strong 2023 Beauty segment results and continued expansion. Contact details provided -
-
-
-
PRESS RELEASE
M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million
M1 Kliniken AG reports sales growth of over 10% to €316.3 million and a 68% increase in EBIT for the fiscal year 2023. Expansion in Eastern Europe and positive outlook for 2024 -
-
